New hope for advanced stomach cancer patients after standard treatments fail
NCT ID NCT06123468
Summary
This study tested a new drug for people with advanced stomach or esophageal cancer that had spread and stopped responding to standard treatments. The drug, called sacituzumab-govitecan, is designed to target cancer cells specifically. Researchers gave the drug to 58 patients to see if it could shrink tumors and control the disease, while also checking for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hämatologisch-Onkologische Praxis Eppendorf
Hamburg, 20249, Germany
-
Klinikum rechts der Isar der TU München
München, 81675, Germany
-
Nationales Centrum für Tumorerkrankungen
Heidelberg, 69120, Germany
-
Onkopraxis Probstheida
Leipzig, 04289, Germany
-
SCRI-CCCIT GmbH
Salzburg, 5020, Austria
-
Universitätsklinikum Jena
Jena, 07747, Germany
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Mannheim
Mannheim, 68167, Germany
Conditions
Explore the condition pages connected to this study.